ABSTRACT Drug resistance is a consequence of how most modern medicines work. Drugs exert pressure on cells that causes death or the evolution of resistance. Indeed, highly specific drugs are rendered ineffective by a single DNA mutation. In this study, we apply the drug methotrexate, which is widely used in cancer and rheumatoid arthritis, and perform evolution experiments on Baker's yeast to ask the different ways in which cells become drug resistant. Because of the conserved nature of biological pathways between yeast and man, our results can inform how the same mechanism may operate to render human cells resistant to treatment. Exposure of cells to small molecules and drug therapies imposes a strong selective pressure. As a result, cells rapidly acquire mutations in order to survive. These include resistant variants of the drug target as well as those that modulate drug transport and detoxification. To systematically explore how cells acquire drug resistance in an unbiased manner, rapid cost-effective approaches are required. Methotrexate, as one of the first rationally designed anticancer drugs, has served as a prototypic example of such acquired resistance. Known methotrexate resistance mechanisms include mutations that increase expression of the dihydrofolate reductase (DHFR) target as well as those that maintain function yet reduce the drug's binding affinity. Recent evidence suggests that target-independent, epistatic mutations can also result in resistance to methotrexate. Currently, however, the relative contribution of such unlinked resistance mutations is not well understood. To address this issue, we took advantage of Saccharomyces cerevisiae as a model eukaryotic system that combined with whole-genome sequencing and a rapid screening methodology, allowed the identification of causative mutations that modulate resistance to methotrexate. We found a recurrent missense mutation in SEC21 (orthologous to human COPG1), which we confirmed in 10 de novo methotrexate-resistant strains. This sec21 allele (S96L) behaves as a recessive, gain-of-function allele, conferring methotrexate resistance that is abrogated by the presence of a wild-type copy of SEC21. These observations indicate that the Sec21p/COPI transport complex has previously uncharacterized roles in modulating methotrexate stress.
many of these therapies are required chronically. One such widely studied example is the antifolate drug methotrexate (MTX). MTX is one of the first examples of rational drug design based on the observation that folic acid stimulated the proliferation of acute lymphoblastic leukemia cells; as such, MTX was designed as an antimetabolite to block the folic acid biosynthesis pathway (for review see Farber et al. 1948; Mikkelsen et al. 2011) . Dihydrofolate reductase (DHFR) is a conserved enzyme in the folic acid biosynthesis pathway which is required for the de novo synthesis of purines, thymidylic acid, and amino acids (Chen et al. 1984; Barclay et al. 1988) . MTX has been successfully used to treat a wide range of cancers, e.g., non-Hodgkin lymphoma, osteosarcoma, and colon cancer. MTX therapy has, however, led cancer cells to evolve various MTX resistance mechanisms, which include mutations that increase production of the DHFR drug target as well as those that reduce the ability of the drug to bind the target (Lewis et al. 1995; Zhao and Goldman 2003; Assaraf 2007; Mikkelsen et al. 2011; Wong et al. 2016) . MTX is also used in other applications, most notably for autoimmune treatment in alleviating the symptoms of rheumatoid arthritis and Crohn's disease. In these cases, its efficacy is, however, less well understood on a mechanistic level (Mikkelsen et al. 2011) and little is known about the development of resistance during these treatments.
There is thus a compelling need to understand the pathways that are affected by MTX treatment and to define the distinct ways in which cells can become resistant to treatment. For example, evidence suggests that target-independent epistatic mutations can contribute to antifolate resistance (Bohanec Grabar et al. 2008; Constanzo and Hartl 2011; Toprak et al. 2012 ). Yet the roles of such target-independent resistance mechanisms are poorly understood either qualitatively or quantitatively which can limit new applications of known drugs, in the case of drug-repurposing efforts. A powerful way to address this challenge is to take an unbiased approach and design an experiment in which the cell reports how methotrexate resistance develops. Toward this end, we used Saccharomyces cerevisiae, a validated eukaryotic model of MTX activity (Cardenas et al. 1999; Hoon et al. 2008; Wong et al. 2016) . Here, we present the results of a resistance screen in wild-type yeast cells to isolate de novo yeast mutants conferring resistance to MTX. Whole-genome sequencing analysis of 10 independent mutants confirmed the emergence of a common sec21 allele (S96L) capable of modulating MTX resistance. The role of SEC21 was further demonstrated by restoration of MTX sensitivity by introduction of wild-type SEC21 by transformation and mating.
MATERIALS AND METHODS

Yeast strains and growth conditions
For wild-type reference strains, diploid BY4743 MATa/MATa his3D1/ his3D1 leu2D0/leu2D0 LYS2/lys2D0 met15D0/MET15D0 ura3D0/ ura3D0 and haploid BY4742 MATa (his3D1 leu2D0 lys2D0 ura3D0) were used in this study. All growth assays were performed using rich media (yeast extract, peptone, dextrose medium, YPD), synthetic complete (SC) media, or synthetic dropout minus uracil (SD-URA). To verify r 0 , cells which lack mitochondrial genome, we tested for growth in obligate respiratory media by culturing cells in YP media with a nonfermentable carbon source (glycerol at 3% v/v). To generate strains in the diploid background, haploid strains were mated to the haploid BY4742 and diploids selected on media lacking lysine and methionine (SD-LYS-MET).
Drug screen
A methotrexate (MTX) resistance assay was performed by plating wildtype BY4741 yeast cells at a density of 6 · 10 4 cells onto three 100-mm 2 petri dishes. Each dish contained YPD agar medium with MTX (Sigma M9929) dissolved at a final 1.2 mM, which is equivalent to a minimum effective concentration that inhibits 20% cell growth (MEC 20 ), based on previously published growth assays (Wong et al. 2016 ). An aliquot of the untreated parent BY4741 strain was archived for subsequent validation experiments. Plated cells were cultured for 7 d (until robust colonies were visible) at 30°in the dark. Of 32 colonies recovered, 10 were confirmed to be drug resistant by exposing the individual colonies to fresh MTX-containing YPD agar media. To further validate the growth fitness of candidate MTX-resistant strains, a liquid growth assay was conducted in a Tecan plate shaker overnight at 30°with vigorous shaking (200 rpm). Optical density readings (O.D. 595 ) were collected over 24 hr in four independent growth assays. Significance of growth differences was assessed with a t-test between the mutant and BY4741 wild-type strains taking into account multiple testing with the Benjamini Hochberg procedure. Figure 1 Drug resistance assay. Wild-type BY4741 cells were screened by plating 6 · 10 4 cells on rich YPD solid media containing methotrexate (1.2 mM, MTX). After 7 d of growth at 30°in the dark, the plate was monitored for the appearance of colonies which were then isolated as single cells. MTX resistance was next independently confirmed by liquid growth assay in the presence of a dose-response of methotrexate. The genomic DNA of the confirmed MTX-resistant colonies was extracted for next-generation sequencing followed by gene variant analysis. Finally genomic alterations identified were validated by complementation assays.
Whole-genome sequencing and analysis Whole-genome sequencing was performed on the confirmed MTXresistant clones and MTX-sensitive wild-type cells. Genomic DNA was extracted from cells using the Gentra Puregene Yeast/Bact. kit (Qiagen) according to the manufacturer's instructions. Genomic DNA was quantified using Qubit fluorometry and Nextera XT libraries prepared following manufacturer recommendations (Illumina). Paired-end sequencing (2 · 101 nt) was conducted on an Illumina HiSequation 2500 in Rapid Run mode. Raw base call data (bcl) were converted into FastQ format using the bcl2fastq conversion software from Illumina (version 1.8.3, setting -no-eamss).
Sequence read pairs were mapped to the yeast reference genome S288C version R64 (downloaded from Saccharomyces Genome Database [SGD] , http://www.yeastgenome.org) using the short-read aligner BWA version 0.7.9 (Li and Durbin 2009). For each sample this resulted in an average sequencing depth ranging from 63· to 144·. Singlenucleotide variants (SNVs) were identified and filtered with the help of the SAMtools toolbox . SNVs also present in the parent strain were eliminated from further consideration. Each SNV was annotated with a custom Perl script and gene information downloaded from SGD on January 21, 2014. The read alignments in the regions of interesting candidate SNVs were visually inspected with the IGV viewer (Robinson et al. 2011; Thorvaldsdottir et al. 2013 ) for further curation. The presence of the mitochondria genome was inferred by measuring the number of reads properly aligning to the mitochondrial reference sequence divided by the length of the mitochondrial genome, and then normalizing that ratio to the equivalent quantity for the nuclear genome. Only wild-type BY4741 cells have mitochondrial genome at a calculated ratio of 1:5.
Yeast transformation and complementation assay
To validate the drug resistance of sec21 variants, all MTX-resistant strains were transformed with a MoBY-SEC21 plasmid (Ho et al. 2009 ) using a high-efficiency LiAc-based transformation protocol (Gietz and Schiestl 2007) . Transformants were grown on YPD medium containing G418 (geneticin) to select for the MoBY-SEC21 plasmid. Each individual MoBY-SEC21 transformed strain was exposed to MTX (1 or 2 mM) in liquid growth assays, as described above.
Data availability MTX-resistant strains are available upon request. All the fastq files are deposited at the NCBI SRA under the accession number SRP082437.
RESULTS
Genome-wide methotrexate resistance screen To isolate MTX-resistant mutants, 6 · 10 4 wild-type cells were plated in three agar plates with lethal doses of MTX and allowed to recover at 30°i n the dark (Figure 1 ). Seven days post-treatment, 32 robust colonies had formed. Ten of these 32 were confirmed as bona fide resistant mutants by growth in media containing MTX (Figure 2 and Materials and Methods). These MTX-resistant mutants showed a range of dosedependent growth in high doses of MTX (MEC 100 2 mM, Wong et al. 2016) , and furthermore, their competitive fitness varied (Figure 2 and Figure 3B ). In the absence of drug challenge, however, all mutants exhibited growth defects relative to the wild type (Figure 2 and Figure   Figure 4 SEC21 complementation assays. As in Figure 1 Genomic variants shared between resistant strains are binned into groups A, B, and C. Unlike the parent BY4741 strain, all mutant strains are r 0 , lacking mitochondrial genome.
3A). This observation that each mutant's fitness was distinct either in the presence or absence of MTX prompted us to determine the wholegenome sequence of each mutant.
Genomic variations underlying methotrexate drug resistance
Whole-genome sequencing was performed for each independent MTXresistant mutant (see Materials and Methods). These data identified a common sec21 missense mutation (S96L) that results in the substitution of serine with leucine at position 96 in all 10 mutants (Table 1 and Supplemental Material, Table S1 ). This recurrent variant strongly suggests that, despite the fact that each of these 10 mutants had other polymorphisms, the sec21(S96L) is a "driver" mutation that resulted in the MTX-resistant phenotype. In addition to the sec21 allele, all mutants were r 0 and devoid of mitochondrial DNA (Table S1 ). Consistent with this observation, none of these mutants was able to grow in obligate respiratory YP media containing glycerol (data not shown). Inhibition of folic acid biosynthesis, which is essential for DNA synthesis, is known to hinder mitochondrial DNA replication and consequently lead to respiration deficiency (Wintersberger and Hirsch 1973; Blount et al. 1997; Stover and Field 2011) . However, respiration deficiency has not been associated specifically with MTX resistance. These observations suggest that, because mitochondrial activity is dispensable for S. cerevisiae growth in fermentation conditions (Yotsuyanagi 1962; Otterstedt et al. 2004) , these mutants can survive in response to MTX at the expense of overall fitness and loss of mitochondrial DNA. Further, our inability to uncover dfr1 mutants is consistent with the fact that we screened haploid yeast (Materials and Methods). Because Dfr1p is an essential enzyme, mutations that compromise MTX drug binding, which are known to abolish the catalytic activity of Dfr1p, would likely be inviable (Wong et al. 2016) . In addition to the sec21(S96L) allele, three out of the 10 mutants (4, 7, and 8) carry a common missense mutation in the VAS1 gene (F227V); two mutants (1 and 10) had three other nonsynonymous mutations: dit1(A39T); fkh1(A443D); rkm1(Y418N) ( Table 1 and Table S1 ). Since DIT1, FKH1, and RKM1 gene functions are required for lifespan and survival (Briza et al. 1990; Porras-Yakushi et al. 2005; Postnikoff et al. 2012) , it is perhaps not surprising that these later two MTX-resistant strains, in particular mutant 10, which carry four independent missense mutations and three additional genomic polymorphisms, manifest the lowest overall fitness ( Figure 3B and Table S1 ).
SEC21 complementation of methotrexate sensitivity
Given that the same sec21(S96L) allele was found in all MTX-resistant mutants, we conducted complementation assays using wild-type SEC21. Specifically, we asked if introduction of a wild-type copy of the essential gene SEC21 on a plasmid (driven by its native promoter) or by generating a SEC21/sec21(S96L) heterozygous diploid by mating was sufficient to restore MTX sensitivity (see Materials and Methods). When SEC21 was expressed in each mutant from a MoBY-SEC21 plasmid (Ho et al. 2009) (Figure 4A ) or by crossing to a wild-type haploid BY4742 strain ( Figure 4B ), in both cases, the resistant mutants were resensitized to MTX. While both strategies restored MTX sensitivity, only the heterozygotes showed wild-type fitness in the absence of MTX. Given that only the heterozygotes contained a functional mitochondrial genome, we speculate that only r + cells are able to manifest wild-type fitness ( Figure 4B ). These observations suggest that sec21 (S96L) acts as a recessive, neomorphic allele to confer MTX resistance. To further support this conclusion, we also found that the greatest degree of MTX sensitivity was achieved when two copies of wild-type SEC21 were expressed in cells ( Figure 5 ). These are consistent with SEC21 representing an indirect target of MTX that nonetheless can confer robust drug resistance in a gene dosage-dependent manner, similarly to DFR1 target (Yan et al. 2009 ).
DISCUSSION
In the current work, we extend the utility of budding yeast as a model system to study drug resistance by identifying and validating de novo mutations capable of conferring resistance to the antifolate drug MTX. Using a growth-based resistance screen combined with whole-genome sequencing, we confirmed that a single "driver" mutation in SEC21 (S96L) (orthologous to the human COPG1) of the COPI coatomer protein complex (Hosobuchi et al. 1992) was associated with previously unknown antifolate tolerance. The protein sequences of yeast Sec21p Figure 5 The effect of SEC21 gene dosage in methotrexate-containing media. As in Figure 1 , growth of yeast strains, BY4741 (SEC21, in light green), haploid mutant 6 [sec21(S96L), in gray], BY4743 (SEC21/SEC21, in black), and heterozygote mutant 6 [SEC21/sec21(S96L), in dark green], was evaluated over time in a Tecan shaker-reader (200 rpm) at 30°. Yeast strains were grown in rich media containing MTX (1 mM, diamond markers) and DMSO (1% v/v, circle markers) . Growth assays were reproduced in three independent experiments. and human ortholog COPG1 are poorly conserved (32% identical), and in both cases, the yeast S96 and human A96 are located at the surface of the protein and have no annotated function (PDB ID 5A1U). Phenotypically, however, this nonsynonymous mutation, sec21(S96L), manifests a gain of MTX resistance phenotype that can be suppressed by the presence of a wild-type copy of SEC21 in a gene dosage-dependent manner (Figure 4 and Figure 5 ). In light of our complementation results, we asked if SEC21 haploinsufficiency can result in MTX-induced growth defects. In fact, in our previously published compendium of chemogenomic profiles (Lee et al. 2014) , sec21D/SEC21 heterozygotes showed a statistically significant MTX-induced growth sensitivity. Together, these findings suggest that sec21(S96L) mutants resemble SEC21/sec21D cells -in both cases cells show increased MTX resistance; and sec21(S96L) mutants behave like partial loss-of-function alleles -in this scenario SEC21 function is required to resist MTX. Further analysis showed that deletion of five out of seven genes in the coatomer complex, specifically SEC26 (human COPB1), SEC27 (human COPB2), RET2 (human ARCN1), COP1 (human COPA), and RET3 (human COPZ), sensitizes yeast cells to the presence of MTX (Lee et al. 2014) . The latter results suggest that these coatomer subunits, which are required for coatomer biogenesis, integrity, and assembly of COPcoated vesicles (Kuge et al. 1993; Beck et al. 2009 ), may be important in mediating the transport of proteins implicated in MTX metabolism and associated metabolic effects that may influence MTX treatment response. In fact, MTX therapy has also been used to alleviate symptoms of arthritis in patients who suffer from COPA syndrome, an immune dysregulatory disease caused by defective COPA gene variants (Vece et al. 2016 ). These observations reveal that the COPI transport complex may have previously uncharacterized roles in modulating methotrexate stress.
Since MTX resistance can be abrogated by the expression of wildtype SEC21 alone, the additional rare mutations acquired by MTXresistant mutants are likely to be nonconsequential with respect to the phenotype, which have emerged as a result of dynamic survival strategies cells evolved to respond to drug selection (Table S1 ). Upon MTX-induced mitochondrial damage, it is not surprising to find additional polymorphisms in genes such as VAS1 and DIT1 that can further impair mitochondria homeostasis, which in turn help cells to eliminate dysfunctional mitochondria to guarantee cell survival (Chatton et al. 1988; Briza et al. 1990; de la Torre-Ruiz et al. 2015) . Particularly, three MTX-resistant mutants with reduced survival fitness emerged with a common vas1(F227V) variant, which potentially disrupts the mitochondrial DNA synthesis given Vasp1 function as an essential mitochondrial valyl-tRNA synthetase (Chatton et al. 1988) . Furthermore, rkm1(Y418N) and fkh1(A443D) mutations, which can alter chromatin state and cell cycle progression (Porras-Yakushi et al. 2005; Postnikoff et al. 2012) , could potentially facilitate the long-term propagation of MTX-resistant cells. Functional studies to further understand the putative effects of these rare mutations will help to uncover the underlying defense mechanisms implicated in antifolate-tolerant cell survival.
Together, these findings suggest that the conserved function of COPI coatomer complex in the intercompartmental vesicle-mediated transport regulation (Duden et al. 1994; Gaynor et al. 1998; Beck et al. 2009 ), plays a key role for the metabolic trafficking of detoxification proteins associated with MTX metabolism and clearance (Stover and Field 2011) . Disruption of the COPI complex may therefore represent a novel cellular pathway to regulate antifolate stress that could ultimately improve antifolate regimes with more tolerable toxicity profiles. Further understanding of the relationship between the secretory pathways, COPI complex, and antifolate metabolism should guide the implementation of better therapeutic strategies to modulate the emergence of drug-resistant variants. ACKNOWLEDGMENTS L.H.W. thanks Julien Bergeron for critical reading input. This work was funded by grants from University of British Columbia Pharmaceutical Sciences and National Aeronautics and Space Administration.
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